Published in Philos Trans R Soc Lond B Biol Sci on August 29, 2005
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol (2009) 1.16
MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics (2011) 1.06
Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metab Dispos (2014) 1.04
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother (2012) 0.95
Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. Trends Cancer Res (2008) 0.87
In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes. Drug Metab Lett (2011) 0.87
Biomarkers: symptoms, survivorship, and quality of life. Semin Oncol Nurs (2012) 0.85
Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomark Med (2011) 0.83
Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS One (2014) 0.83
Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models. J Biol Chem (2013) 0.82
Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep (2014) 0.81
Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urol Oncol (2012) 0.81
Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. Eur J Clin Pharmacol (2008) 0.79
A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. Malar J (2009) 0.78
Introduction: genetic variation and human health. Philos Trans R Soc Lond B Biol Sci (2005) 0.75
The International HapMap Project. Nature (2003) 73.65
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Inheritance and drug response. N Engl J Med (2003) 5.78
Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics (2004) 5.12
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J (2005) 3.51
Moving towards individualized medicine with pharmacogenomics. Nature (2004) 2.99
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med (2004) 2.83
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet (2004) 2.44
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet (1997) 2.34
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics (2000) 1.94
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther (2005) 1.83
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 1.79
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci (1999) 1.77
Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem (1997) 1.76
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol (2002) 1.75
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther (2003) 1.74
Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther (2003) 1.65
Pharmacogenetics and cancer therapy. Nat Rev Cancer (2001) 1.62
Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet (2004) 1.59
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med (1998) 1.51
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.50
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J (2003) 1.44
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther (2005) 1.35
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain (1999) 1.28
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos (2003) 1.20
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet (2002) 1.10
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem (2002) 1.10
The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics (1995) 1.09
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit (1997) 1.08
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol (2003) 1.08
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol (2003) 1.03
Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics (2005) 0.99
CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics (2005) 0.97
A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci (1997) 0.92
The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene (2000) 0.90
Pharmacogenetics of irinotecan toxicity. Pharmacogenomics (2004) 0.89
Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther (2005) 0.87
A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J Biol Chem (2005) 0.81
Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anticancer Agents (2005) 0.79
Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther (2000) 0.77
Defining relationships between the known members of the cytochrome P450 3A subfamily, including five putative chimpanzee members. Mol Phylogenet Evol (2004) 0.77
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther (2007) 3.35
Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One (2012) 1.10
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun (2006) 1.02
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders. CNS Drugs (2009) 0.89
Molecular markers to predict response to therapy. Semin Oncol (2013) 0.83
The role of pharmacogenetics and pharmacogenomics in 21st-century medicine: state of the art and new challenges discussed in the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF). Drug Metabol Personal Ther (2016) 0.75
Novel aspects of drug metabolism and transport. Drug News Perspect (2006) 0.75
New approaches and applications in chemical biology. Drug News Perspect (2004) 0.75